Janux Therapeutics
JANX
Janux Therapeutics (JANX) news
Recent news
Janux Therapeutics 2Q loss/share 35c, est. loss/share 25c
AInvest Wire · Aug 6, 2026Janux Therapeutics Inc: Truist Securities assumes coverage with buy rating; target price $26 vs $80
AInvest Wire · Jun 25, 2026ImportantJanux Therapeutics jumps 62% in premarket trading after it announced positive updated interim clinical data for its JANX007 clinical program.
Janux Therapeutics jumps 62% in premarket trading after it announced positive updated interim clinical data for its JANX007 clinical program. Janux Therapeutics, Inc. (JANUX) experienced a significant pre-market surge of 62% on February 21, 2024, following the announcement of positive updated…
AInvest Wire · Dec 3, 2024ImportantJanux Therapeutics resumes, trims gain to about 150%.
AInvest Wire · Feb 27, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.